These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 20976952)

  • 1. [The incidence of extended spectrum beta-lactamases in Proteus mirabilis strains isolated in 2007-2009].
    Kwiecińska-Piróg J; Bogiel T; Gospodarek E
    Przegl Epidemiol; 2010; 64(3):395-8. PubMed ID: 20976952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The susceptibility of Proteus mirabilis strains isolated from white stork (Ciconia ciconia)].
    Kwiecińska-Piróg J; Bogiel T; Gospodarek E; Kasprzak M; Jerzak L; Kamiński P
    Med Dosw Mikrobiol; 2011; 63(2):139-44. PubMed ID: 22184908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.
    Endimiani A; Luzzaro F; Brigante G; Perilli M; Lombardi G; Amicosante G; Rossolini GM; Toniolo A
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2598-605. PubMed ID: 15980325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.
    Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F
    J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug resistance and proticinogenic types of Proteus mirabilis isolated from urinary tract infections].
    Szymaniak L; Aleksandrowicz I; Giedrys-Kalemba S
    Med Dosw Mikrobiol; 1999; 51(3-4):323-30. PubMed ID: 10803261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients.
    Saito R; Okugawa S; Kumita W; Sato K; Chida T; Okamura N; Moriya K; Koike K
    Clin Microbiol Infect; 2007 Dec; 13(12):1204-6. PubMed ID: 17850340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan.
    Wu LT; Wu HJ; Chung JG; Chuang YC; Cheng KC; Yu WL
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):89-94. PubMed ID: 16406185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of Proteus mirabilis isolates producing TEM-52 extended-spectrum beta-lactamases in Croatia.
    Sardelić S; Bedenić B; Sijak D; Colinon C; Kalenić S
    Chemotherapy; 2010; 56(3):208-13. PubMed ID: 20551637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular diversity of Proteus mirabilis isolates producing extended-spectrum beta-lactamases in a French university hospital.
    Biendo M; Thomas D; Laurans G; Hamdad-Daoudi F; Canarelli B; Rousseau F; Castelain S; Eb F
    Clin Microbiol Infect; 2005 May; 11(5):395-401. PubMed ID: 15819867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of plasmid-encoded extended spectrum beta-lactamases produced by a clinical strain of Proteus mirabilis.
    Mahrouki S; Ben-Achour N; Chouchani C; Ben-Moussa M; Belhadj O
    Pathol Biol (Paris); 2009 May; 57(3):e55-9. PubMed ID: 18456422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in biofilm formation and aggregative adherence between beta-lactam susceptible and beta-lactamases producing P. mirabilis clinical isolates.
    Nucleo E; Fugazza G; Migliavacca R; Spalla M; Comelli M; Pagani L; Debiaggi M
    New Microbiol; 2010 Jan; 33(1):37-45. PubMed ID: 20402412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates.
    Yong D; Lim YS; Roh KH; Choi YS; Park DY; Yum JH; Kim JM; Lee K; Chong Y
    Diagn Microbiol Infect Dis; 2006 Mar; 54(3):237-9. PubMed ID: 16427241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEB-6 extended-spectrum beta-lactamase-producing Proteus mirabilis from Sultanate of Oman.
    Potron A; Poirel L; Elhag K; Al Yaqoubi F; Nordmann P
    Int J Antimicrob Agents; 2009 Nov; 34(5):493-4. PubMed ID: 19525094
    [No Abstract]   [Full Text] [Related]  

  • 14. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
    Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
    Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence of extended-spectrum (beta)-lactamases and plasmid-mediated AmpC (beta)-lactamases among Korean isolates of Proteus mirabilis.
    Park YJ; Lee S; Kim YR; Oh EJ; Woo GJ; Lee K
    J Antimicrob Chemother; 2006 Jan; 57(1):156-8. PubMed ID: 16284101
    [No Abstract]   [Full Text] [Related]  

  • 16. Outbreak caused by Proteus mirabilis isolates producing weakly expressed TEM-derived extended-spectrum β-lactamase in spinal cord injury patients with recurrent bacteriuria.
    Cremet L; Bemer P; Rome J; Juvin ME; Navas D; Bourigault C; Guillouzouic A; Caroff N; Lepelletier D; Asseray N; Perrouin-Verbe B; Corvec S
    Scand J Infect Dis; 2011 Dec; 43(11-12):957-61. PubMed ID: 21888562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevalence of multidrug-resistant Proteus spp. strains in clinical specimens and their susceptibility to antibiotics].
    Reśliński A; Gospodarek E; Mikucka A
    Med Dosw Mikrobiol; 2005; 57(2):175-84. PubMed ID: 16134389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea.
    Ahn JY; Ann HW; Jeon Y; Ahn MY; Oh DH; Kim YC; Kim EJ; Song JE; Jung IY; Kim MH; Jeong W; Ku NS; Jeong SJ; Choi JY; Yong D; Song YG; Kim JM
    BMC Infect Dis; 2017 May; 17(1):327. PubMed ID: 28468622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
    Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
    Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-spectrum β-lactamase-producing Proteus mirabilis with multidrug resistance isolated from raw chicken in Singapore: Genotypic and phenotypic analysis.
    Guo S; Aung KT; Tay MYF; Seow KLG; Ng LC; Schlundt J
    J Glob Antimicrob Resist; 2019 Dec; 19():252-254. PubMed ID: 31639544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.